Skip to main content

Table 2 Therapeutic characteristics

From: Normalization of tumor markers and a clear resection margin affect progression-free survival of patients with unresectable pancreatic cancer who have undergone conversion surgery

 

UPC

n = 67

LAPC

n = 53

MPC

n = 14

Chemotherapy regimens

 based on mFFX

60 (90)

47 (89)

13 (93)

 GnP

4 (6)

3 (6)

1 (7)

 Sequential use of GnP and mFFX

3 (4)

3 (6)

0 (0)

 Duration of systemic treatment (months)

4.53 (1.83–14.47)

4.17 (1.83–12.03)

6.52 (2.33–14.47)

Treatment response

 PR

35 (52)

24 (45)

11 (79)

 SD

32 (48)

29 (55)

3 (21)

Change in levels of preoperative tumor markers

 Decrease to normal

24 (36)

17 (32)

7 (50)

 Decrease > 50% without normalization

22 (33)

18 (34)

4 (29)

 Decrease < 50% or stable

13 (19)

11 (21)

2 (14)

 Negative before treatment

8 (12)

7 (13)

1 (7)

Adverse events (grade)

 0

6 (9)

2 (4)

4 (29)

 1

10 (15)

8 (15)

2 (14)

 2

17 (25)

16 (30)

1 (7)

 3

29 (43)

24 (45)

5 (36)

 4

5 (7)

3 (6)

2 (14)

Severe adverse events

 Neutropenia

23(34)

18(34)

5(36)

 Anemia

11(16)

7(13)

4(29)

 Thrombocytopenia

8(12)

5(9)

3(21)

 Febrile neutropenia

3(4)

3(6)

0(0)

 Fatigue

2(3)

2(4)

0(0)

  1. mFFX modified-FOLFIRINOX, GnP gemcitabine plus nab-paclitaxel, ALT, alanine aminotransferase, PR partial response, SD stable disease